Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label nedosiran in PH1 with severe renal impairment
2024-512259-19-00Phase 2Authorised
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Sep 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of nedosiran in Primary Hyperoxaluria Type 1 (PH1), sponsored by Dicerna Pharmaceuticals, Inc. Primary endpoint: Primary: Change in plasma oxalate from baseline to Day 180. Planned start Sep 2024; status: authorised.
02
Drugs
nedosiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on 2024-512259-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512259-19-00.